Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Fate Therapeutics begins phase II trial of ProHema for hematologic malignancies

March 13, 2014

Innate Pharma continues phase II trial of lirilumab in AML based on DSMB recommendation

March 12, 2014

Northwest Biotherapeutics obtains German approvals for DCVax-L programs

March 11, 2014

Independent committee recommends continuation of phase III trial of algenpantucel-L

March 10, 2014

Janssen Biotech to begin phase III study of daratumumab in multiple myeloma

March 6, 2014

Data monitoring committee recommends termination of METLung study of onartuzumab

March 3, 2014

New fusion proteins designed for cancer and autoimmune diseases

March 3, 2014

U.S. researchers disclose new EGFRvIII-derived cancer vaccines

Feb. 28, 2014

ImmunoCellular Therapeutics receives orphan drug status in Europe for ICT-107 in glioblastoma

Feb. 26, 2014

OncoMed Pharmaceuticals begins third phase Ib trial of OMP-54F28

Feb. 21, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.